What is the evidence that hydroxyurea improves health-related quality of life in patients with sickle cell disease? Hematology Am Soc Hematol Educ Program 2012;2012:290-1
Date
12/13/2012Pubmed ID
23233594DOI
10.1182/asheducation-2012.1.290Scopus ID
2-s2.0-84879394678 (requires institutional sign-in at Scopus site) 12 CitationsAbstract
A 10-year-old male patient with homozygous sickle cell disease presents for a follow-up clinic visit after a recent hospitalization for a painful vasoocclusive event. His parents mention that in the past year he has had 4 hospitalizations for vasoocclusive events, 2 of which were complicated by the development of acute chest syndrome that resulted in transfer to the intensive care unit. He has missed many school days and may be retained a grade this year. He feels particularly sad about missing the school field trip that occurred during his last hospitalization. He also reports that he is not able to keep up with his friends when participating in physical activities at school. The child's parents are worried that he may be depressed. You as the provider discuss the option of hydroxyurea therapy. His parents ask if hydroxyurea would improve his overall well-being and functioning.
Author List
Darbari DS, Panepinto JAMESH terms used to index this publication - Major topics in bold
Acute DiseaseAdult
Affect
Anemia, Sickle Cell
Child
Cohort Studies
Critical Care
Cross-Sectional Studies
Hospitalization
Humans
Hydroxyurea
Male
Multicenter Studies as Topic
Quality of Life
Randomized Controlled Trials as Topic
Retrospective Studies
Treatment Outcome
